Toxicogenomics in the USA Pfizer, Global Research & Development Drug Safety Evaluation Ikuo HORII - Molecular toxicological approach in drug di scovery and development - Current use of toxicogenomics in preclinica l studies under assessing the current limitations and future promise
Toxicogenomics in the USA. - Molecular toxicological approach in drug discovery and development - Current use of toxicogenomics in preclinical studies under assessing the current limitations and future promise. Pfizer, Global Research & Development Drug Safety Evaluation - PowerPoint PPT Presentation
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Toxicogenomics in the USA
Pfizer, Global Research & Development
Drug Safety Evaluation
Ikuo HORII
- Molecular toxicological approach in drug discovery and development
- Current use of toxicogenomics in preclinical studies under assessing the current limitations and future promise
Gene related FactorEnvironment
Diet
Life-style
Genes OrgansDisease
Side Effect
Medicines
Toxicity directly caused by DNA damage Critical !!! (Mutagenicity, Carcinogenicity, etc.)Toxicity indirectly derived from the changes of related gene expression Manageable !
Disease is the outcome of the interaction between genes and environment
Most toxicologically relevant outcomes require differential expression of multiple genes.
If toxicity manifested at the level of organism is preceded by altered expression of related genes, its detection can serve as an early warning for subsequent deleterious outcomes
Miniaturization and automation of new tools for analysis of gene expression and metabolic networking allow the molecular life of cells to be studied at a more holistic (and complex) level than was previously possible
Gene expression and toxicology
Targeted Effect
Molecular Toxicological Approach for Safety Assessment
• Many compounds • Small amount of comp.• Molecular-targeted comp.
Change of toxicological approach Introduction of new technology
Candidate CompoundLeadsScreening
Nos of Compound Cost / Resources
IND(Entry into human) NDA
SRA/SRT
ToxicogenomicsToxicoproteomicsMetabolomics
Molecular Toxicology Toxicopanomics + New Science
Study Design for Toxicogenomics/Toxicoproteomics Assessment
Detection - Gene expression : Gene chip analysis, etc - Protein synthesis : 2-D Electrophoresis, Protein analysisStudy Design (Comparison with known toxic-compounds under the database)
In vivo Normal(non-treat) & Treated - Non - change In vitro Cell / Organ / Tissue - Up - regulation - Down - regulation
Significance of Toxicogemonics / Toxicoproteomics Approach--- Mechanistic investigation & prediction of toxicity ---
Mechanistic Tox. Study
Study result - Tox.related gene / protein - Mechanistic related metabolic pathway / action site
Tox. Prediction Study - Expression profile of gene / protein in new compounds Prediction of Toxicity - Comparison of profiles with existing ( Strategy of drug discovery ) gene-related toxicological database
Genes on the toxicology gene chip
Functional group Type of genesStress response Oncogenes
The 2002 Workshop on Pharmacogenetics/Pharmacogenomics in Drug Development and Regulatory Decision-Making
--- Sponsored jointly the FDA, DruSafe PhRMA and PWG --- May 16 - 17, 2002 at the University of Maryland, Shady Grove Conference Center
Toxicogenomics in Drug Development : Where are we today & where are we going ?Industry and regulatory agencies viewed this meeting as an opportunityto discuss how such data should be included/evaluated in IND and NDAapplications.
Where are we now ?Where would we like to be ?
(1) Is toxicogenomic science and validation technology sufficiently mature to reply upon genomic data for safety decisions and to justify the routine use of genomic data in GLP toxicology studies ?
Current toxicogenomic data is not being collected in GLP studies, and the data is difficult to interpret and do not add to standard toxicology assays.
However, genomic data is useful in mechanistic studies, and if done with IND compounds, the data should be submitted. There was some consensus that genomic data may be added to standard toxicology data, but we need to explore the “safe harbor” concept with FDA.
(2) Where is the value of toxicogenomic data to Industry and the FDA ?
The value of toxicogenomic data now is in mechanistic studies and hypothesis testing and not predictive data in risk assessment.
Most would like to develop more confidence in data, share data with FDA.
(3) How could data from genomic arrays, in conjunction with standard short-term toxicology studies, be used to assist in study design or in species selection for long-term toxicology studies ?
The toxicogenomics is not well understood presently to be predictive, especially outside the rat/mouse species, of the human response.
The standard toxicology studies need not include or be replaced by genomics, but genomic data may be used to better design of toxicology.
(4) Is there a need for guidance in the toxicogenomics area ? If guidance’s existed what wold be their main purpose and what would be the potential impact ?
A regulatory guidance document is not necessary at this time. However, standard practice for reviewing data needs to be made transparent and a consensus of how data should be submitted would be useful.
Thus, a white paper on how to review genomic data, within FDA, for internal consistency is recommended.
(5) Development of “historic databases” in interpreting toxicogenomic findings may be useful if the data are robust and reliable and if toxicogenomics profiles predict toxicities.If this is correct, how should such databases be developed and utilized ?
The development of some form of knowledge base rather than a historical database for interpreting toxicogenomic findings.
Since the technology is emerging, and data is limited, the potential of genomic data is a “red flag” awareness to evaluate in other toxicological assays.
As a conclusion,The application of toxicogenomics disciplinesranges from hypothesis testing of toxicity to safety evaluation. However, validation of the results for use in registration and marketing is limited and canonly be evaluated on a case by case basis at thepresent time.As we progress, the regulatory implications oftoxicogenomic data will be transparent and lead to relevant guidance documents.